Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris
In All, PortfolioFirst program from the Topas platform to enter clinical testing PM203 is one of several proprietary programs being developed by Topas Pemphigus vulgaris is an orphan indication that currently has no cure Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural…